Niagen Bioscience, Inc. the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, announced the inaugural hotel debut of Tru Niagen® as an in-room amenity at the Equinox Hotel New York, and Niagen IV, now available at the hotel’s spa through NutriDrip
A new independent study has revalidated the use of C15:0 to reverse core components of a newly discovered nutritional C15:0 deficiency syndrome, called Cellular Fragility Syndrome, which may be impacting as many as 1 in 3 people globally.
Fresenius announced that its operating company Fresenius Kabi, has introduced two new biosimilars - Conexxence® (denosumab-bnht) and Bomyntra® (denosumab-bnht) - in the United States.
Incyte announced that the U.S. Food and Drug Administration (FDA) has approved Monjuvi® (tafasitamab-cxix), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, in combination with rituximab and lenalidomide for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL).
Alcon the global leader in eye care dedicated to helping people see brilliantly, announced the approval of Clareon® PanOptix® Pro intraocular lens (IOL) for cataract patients in Canada. PanOptix Pro leverages proprietary ENLIGHTEN® NXT Optical technology which delivers the lowest light scatter and highest reported light utilization of any trifocal IOL.1-3,5-9,**,‡‡ PanOptix Pro provides an unprecedented 94% light utilization, compared to a theoretical maximum utilization of 96% for diffractive optics.
CollPlant Biotechnologies a regenerative and aesthetics medicine company developing innovative technologies and products based on its plant-derived, Type I recombinant human collagen (rhCollagen) for tissue regeneration and medical aesthetics, announced the expansion of its agreement with STEMCELL Technologies, a biotechnology company that develops and supplies specialized cell culture media, tools, and services to support research in stem cell biology, regenerative medicine, immunology, and related life sciences.
Lubrizol announces that an Apisolex™ polymer excipient-enabled drug formulation is in Phase 1 clinical trials.
Bruker Corporation announced the acquisition of biocrates life sciences ag, located in Innsbruck, Austria. Financial terms were not disclosed. Biocrates is a global leader in mass spectrometry (MS)-based quantitative metabolite and lipid analysis kits, assays, software and services that make standardized metabolomics accessible to laboratories worldwide.
Bruker Corporation announced that its Applied Mass Spectrometry (Applied MS) division will present a powerful lineup of innovations at the These developments reflect Bruker’s continued investment in applied markets, particularly in therapeutic drug monitoring (TDM), drugs of abuse (DoA) analysis and environmental analysis.
STEMCELL Technologies, Canada’s largest biotechnology company, is pleased to announce the acquisition of Cellular Highways Ltd from TTP Group Ltd. Cellular Highways is a biotechnology company based near Cambridge, United Kingdom, that specializes in advanced cell sorting technologies with applications in cell and gene therapy, drug discovery, and general cell research, especially where cells are fragile.